Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.

MLA

Kemeny, N., et al. “Phase I Trial of Adjuvant Hepatic Arterial Infusion (HAI) with Floxuridine (FUDR) and Dexamethasone plus Systemic Oxaliplatin, 5-Fluorouracil and Leucovorin in Patients with Resected Liver Metastases from Colorectal Cancer.” Annals of Oncology, vol. 20, no. 7, July 2009, pp. 1236–41. EBSCOhost, https://doi.org/10.1093/annonc/mdn769.

APA

Kemeny, N., Capanu, M., D’Angelica, M., Jarnagin, W., Haviland, D., Dematteo, R., & Fong, Y. (2009). Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of Oncology, 20(7), 1236–1241. https://doi.org/10.1093/annonc/mdn769

Chicago

Kemeny, N., M. Capanu, M. D’Angelica, W. Jarnagin, D. Haviland, R. Dematteo, and Y. Fong. 2009. “Phase I Trial of Adjuvant Hepatic Arterial Infusion (HAI) with Floxuridine (FUDR) and Dexamethasone plus Systemic Oxaliplatin, 5-Fluorouracil and Leucovorin in Patients with Resected Liver Metastases from Colorectal Cancer.” Annals of Oncology 20 (7): 1236–41. doi:10.1093/annonc/mdn769.